Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in ...

GLP1 drugs are changing patients eating and grocery shopping habits - 2 News Oklahoma's Cathy Tatom hears how from a patient, ...

News Evidence That GLP-1 Drugs Achieve Weight Loss Primarily by Reducing Fat Mass More Than Muscle. Diabetes and obesity have become pressing health issues worldwide. Glucagon-lik ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

You may have heard of "Ozempic face" and "Ozempic butt." Well, now there's "Ozempic mouth" and "Ozempic feet" to describe ...

In patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is not associated ...

GLP-1 receptor agonists are reshaping obesity care. OHE highlights access challenges, prescribing policy, and how patient and ...

Liraglutide and semaglutide reduce alcohol intake, cutting it by nearly two-thirds within four months of treatment.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on ...

New research being presented at the European Congress on Obesity (ECO 2025) has found that patients of an online obesity ...

Landmark research suggests the appetite-suppressing jabs which mimic a hormone that makes us feel full also significantly cut ...